FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to application in an effective amount and to new nicotine receptor agonists described by general formula (i) or (ii) for treating inflammatory diseases chosen from a group including asthma, chronic obstructive pulmonary disease (COPD), interstitial pulmonary tissue fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis (HP), chronic hypersensitivity pneumonitis and bronchiolitis obliterans organising pneumonia (BOOP). The compounds (i) and compounds (ii) relate to formulae (i) (ii) where in formula (i) R1 and R2 independently mean alkyl with 1-10 carbon atoms; Xa means CH or N; Ya means one or more substitutes chosen from hydrogen, halogen, cyano, hydroxyl, alkyl with 1-10 carbon atoms optionally substituted with one or more halogen atoms, and alkoxy with 1-10 carbon atoms; n means an integer 0 or 2; J means a counterion representing a compound for maintaining electric neutrality, e.g., halogen, sulphate, sulphonate; in formula (ii) R3 is chosen from or Xb means N or N+-R10; R4 means one or more substitutes chosen from hydrogen, halogen; each R10, R11 and R12 independently means alkyl with 1-10 carbon atoms; provided the presence of the counterion when Xb means N+-R10.
EFFECT: use of nicotine receptor agonists in the effective amount for treating inflammatory diseases.
26 cl, 40 dwg, 3 tbl, 38 ex
Title |
Year |
Author |
Number |
AGONISTS OF NICOTINE RECEPTORS IN TREATMENT OF INFLAMMATORY DISEASES |
2002 |
- Korm'E Ivon
- Israehl'-Assajag Ehvelin
- Blanshe Mari-Rene
|
RU2299731C2 |
METHOD OF ACTIVATION OF REGULATORY T-CELLS OF ALPHA-2B ADRENERGIC RECEPTOR AGONISTS |
2011 |
- Dzhil Deniel V.
- Donello Dzhon E.
- Lurs Loren M.B.
- Visvanat Veena
|
RU2599495C2 |
APPLICATION OF CB1 RECEPTOR ANTAGONISTS FOR PREPARATION OF COMPOSITION APPLICABLE FOR TREATMENT OF HEPATIC DISEASES |
2005 |
- Lotershtajn Sofi
- Mallat Arian
- Grenar Paskal'
- Zhul'En Boris
- Tran Van Njuen Zhan
|
RU2402328C2 |
METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING ANGIOTENSIN-ASSOCIATED DISEASES |
2014 |
- Petasis Nikos A.
- Rodzhers Ketlin E.
- Lui Sten G.
- Dizerega Gir S.
- Gaffni Kevin Dzh.
|
RU2688163C2 |
NEW COMPOUND FOR DIRECT INHIBITION OF ASM ACTIVITY, WHICH IS DERIVATIVE OF 2-AMINO-2-(1,2,3-TRIAZOL-4-YL)PROPANE-1,3-DIOL, AND ITS APPLICATION |
2019 |
- Bae, Jae-Sung
- Jin, Hee Kyung
- Park, Min Hee
|
RU2759856C1 |
DERIVATIVES OF 1,2-DIAMINOPENTANE AS ANTAGONISTS OF CCR-3 RECEPTORS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF |
2002 |
|
RU2286339C2 |
USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS |
2010 |
- Bergmann John E.
- Cutshall Neil S.
- Demopulos Gregory A.
- Florio Vincent A.
- Gaitanaris George
- Gray Patrick
- Hohmann John
- Onrust Rene
- Zeng Hongkui
|
RU2600869C2 |
OXIDISED LIPIDES AND USE THEREOF FOR TREATING INFLAMMATORY DISEASES AND DISORDERS |
2009 |
- Kharats Dror
- Dzhordzh Jakob
- Khal'Perin Gideon
- Jakov Niva
- Kovalevski-Ishai Ehti
|
RU2482854C2 |
NOVEL PIPERIDINE SUBSTITUTED INDOLES AND HETERODERIVATIVES THEREOF |
2004 |
- Martajrs Domnik
- Anderskevitts Ral'F
- Dollinger Khorst
- Puze Paskal'
- Birke Frants
- Buissu T'Erri
|
RU2382037C2 |
COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR |
2005 |
|
RU2415678C2 |